• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Cadila Pharma expands oncology portfolio with biosimilar cancer drug Bevaro

expresspharmaJuly 23, 2020

Tag: Cadila Pharma , Bevaro , Bevasizumab , Cancer

Ahmedabad-based Cadila Pharmaceuticals recently announced the launch of Bevasizumab biosimilar for the domestic market. Bevacizumab biosimilar is a humanized monoclonal antibody, recommended in multiple indications and will be launched under the brand name Bevaro.

Bevasizumab is used in the treatment of multiple cancers which are common in India like Ovarian Cancer, Glioblastoma Multiforme (a type of Brain cancer), Colorectal Cancer, Breast Cancer, Lung Cancer, Cervical Cancer and Kidney Cancer.

In a commitment to further strengthen the oncology portfolio Cadila’s Bevaro will be made available in a single-dose vial of two strengths, 100 mg, and 400mg.

Cadila plans to launch multiple biosimilar products this year for the Indian market.


Previous:Govt issues notification on PLI Scheme with a few amendments

Next:FDA Extends Enforcement Discretion Policy for Certain Regenerative Medicine Products

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Cadila Pharma expands oncology portfolio with biosimilar cancer drug Bevaro | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China

Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China
oxaliplatino EP/USP Pharmaceutical API Drug treatment of colorectal cancer made in china

oxaliplatino EP/USP Pharmaceutical API Drug treatment of colorectal cancer made in china
Tralostam/Tralostam (can be used to treat breast cancer and dog Cushing's syndrome)

Tralostam/Tralostam (can be used to treat breast cancer and dog Cushing's syndrome)
Natural red Chilly Seed oil with 1-10 Capsaicine for lower cholesterol and The prevention of cancer

Natural red Chilly Seed oil with 1-10 Capsaicine for lower cholesterol and The prevention of cancer

Paclitaxel semi-synthetic and natural USP cancer

Paclitaxel semi-synthetic and natural USP cancer
Toremifene citrate for Anticancer in China 99% GMP

Toremifene citrate for Anticancer in China 99% GMP
Hydroxypropyl beta cyclodextrin in the anticancer drug oxaliplatin

Hydroxypropyl beta cyclodextrin in the anticancer drug oxaliplatin
Anticancer Product Green tea Extract Powder. Tea Polyphenols

Anticancer Product Green tea Extract Powder. Tea Polyphenols

Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer

Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer
Nimustine hydrochloride 99%min Pharmaceutical API Nitrosourea drugs Anti cancer drugs made in china

Nimustine hydrochloride 99%min Pharmaceutical API Nitrosourea drugs Anti cancer drugs made in china

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service